XLO
Xilio Development IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$45.80M
P/E Ratio
—
EPS
$-4.19
Beta
-0.12
52W High
$16.52
52W Low
$6.47
50-Day MA
$8.02
200-Day MA
$9.47
Dividend Yield
—
Profit Margin
-80.00%
Forward P/E
—
PEG Ratio
—
About Xilio Development Inc
Xilio Therapeutics, Inc., a biotechnology company, designs immunotherapies to improve the immune systems of cancer patients. The company is headquartered in Waltham, Massachusetts.
Fundamentals
| Revenue (TTM) | $43.77M |
| Gross Profit (TTM) | $43.77M |
| EBITDA | $-40.44M |
| Operating Margin | -86.50% |
| Return on Equity | -132.50% |
| Return on Assets | -23.30% |
| Revenue/Share (TTM) | $9.66 |
| Book Value | $7.79 |
| Price-to-Book | 1.34 |
| Price-to-Sales (TTM) | 1.05 |
| EV/Revenue | 10.21 |
| EV/EBITDA | -0.11 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 694.00% |
| Shares Outstanding | $5.78M |
| Float | $3.45M |
| % Insiders | 29.48% |
| % Institutions | 35.38% |
Historical Volatility
HV 10-Day
27.29%
HV 20-Day
24.67%
HV 30-Day
41.35%
HV 60-Day
49.89%
HV Rank
—
Volatility is currently contracting
Data last updated: 4/29/2026